- Home
- IMMX vs VTGN Comparison
IMMX vs VTGN Comparison
Compare IMMX & VTGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMMX
- VTGN
- Stock Information
- Founded
- IMMX 2014
- VTGN 1998
- Country
- IMMX United States
- VTGN United States
- Employees
- IMMX N/A
- VTGN N/A
- Industry
- IMMX Medicinal Chemicals and Botanical Products
- VTGN Biotechnology: Pharmaceutical Preparations
- Sector
- IMMX Health Care
- VTGN Health Care
- Exchange
- IMMX Nasdaq
- VTGN Nasdaq
- Market Cap
- IMMX 61.1M
- VTGN 70.0M
- IPO Year
- IMMX 2021
- VTGN N/A
- Fundamental
- Price
- IMMX $2.19
- VTGN $2.02
- Analyst Decision
- IMMX Strong Buy
- VTGN
- Analyst Count
- IMMX 1
- VTGN 0
- Target Price
- IMMX $7.00
- VTGN N/A
- AVG Volume (30 Days)
- IMMX 261.4K
- VTGN 183.5K
- Earning Date
- IMMX 08-11-2025
- VTGN 06-17-2025
- Dividend Yield
- IMMX N/A
- VTGN N/A
- EPS Growth
- IMMX N/A
- VTGN N/A
- EPS
- IMMX N/A
- VTGN N/A
- Revenue
- IMMX N/A
- VTGN $486,000.00
- Revenue This Year
- IMMX N/A
- VTGN N/A
- Revenue Next Year
- IMMX N/A
- VTGN $943.32
- P/E Ratio
- IMMX N/A
- VTGN N/A
- Revenue Growth
- IMMX N/A
- VTGN N/A
- 52 Week Low
- IMMX $1.26
- VTGN $1.90
- 52 Week High
- IMMX $3.00
- VTGN $4.21
- Technical
- Relative Strength Index (RSI)
- IMMX 45.97
- VTGN 38.62
- Support Level
- IMMX $2.16
- VTGN $1.96
- Resistance Level
- IMMX $2.31
- VTGN $2.12
- Average True Range (ATR)
- IMMX 0.17
- VTGN 0.15
- MACD
- IMMX -0.04
- VTGN -0.02
- Stochastic Oscillator
- IMMX 11.14
- VTGN 11.61
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.
About VTGN VistaGen Therapeutics Inc.
Vistagen Therapeutics Inc is a biotechnology firm. The company is neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on deep understanding of nose-to-brain neurocircuitry.